Aarti DrugsNSE:AARTIDRUGS +0.37%77 Days Payable is 96.81 as of Mar. 2026, which is 24% above its 10-year median of 78.18. GuruFocus rates NSE:AARTIDRUGS with a GF Score™ of 77/100 and a GF Value™ of ₹498.33 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 927 Drug Manufacturers companies, Aarti Drugs ranks better than 53.51% on this metric.
Aarti Drugs's average Accounts Payable for the
three
months ended in Mar. 2026 was ₹4,779 Mil. Aarti Drugs's Cost of Goods Sold for the
three
months ended in Mar. 2026 was ₹4,504 Mil.
Hence, Aarti Drugs's Days Payable for the
three
months ended in Mar. 2026 was 96.81.
The historical rank and industry rank for Aarti Drugs's Days Payable or its related term are showing as below:
NSE:AARTIDRUGS'
s Days Payable Range Over the Past 10 Years
Min: 73.36 Med: 78.18 Max: 104.56
Current: 96.85
During the past 13 years, Aarti Drugs's highest Days Payable was 104.56. The lowest was 73.36. And the median was 78.18.
NSE:AARTIDRUGS's Days Payable is ranked better than 53.51% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs NSE:AARTIDRUGS: 96.85
Aarti Drugs's Days Payable
increased
from Mar. 2025 (90.91) to Mar. 2026 (96.81).
It may suggest that Aarti Drugsdelayed paying its suppliers.
Aarti Drugs Days Payable Related Terms
Aarti Drugs Days Payable Historical Data
* Premium members only.
The historical data trend for Aarti Drugs's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:AARTIDRUGS vs ZTS, UTHR: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Drugs's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aarti Drugs Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aarti Drugs's Days Payable distribution charts can be found below:
* The bar in red indicates where Aarti Drugs's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Aarti Drugs's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aarti Drugs (NSE:AARTIDRUGS) has a Days Payable of 96.81 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aarti Drugs and its competitors. This is 24% above median its historical median of 78.18. Over the past decade, Aarti Drugs' Days Payable has ranged from 73.36 to 104.56. According to the industry distribution chart, Aarti Drugs ranks #431 out of 927 companies in the Drug Manufacturers industry, placing it in the top 46.5%.
Is Aarti Drugs' Days Payable too high?
Aarti Drugs' current Days Payable of 96.81 is 24% above median its 10-year median of 78.18. Over the past 10 years, this metric has ranged from a low of 73.36 to a high of 104.56. The Drug Manufacturers industry median Days Payable is 90.38. Aarti Drugs' value of 96.81 is 7.1% above this industry median. Based on the distribution chart, Aarti Drugs ranks #431 out of 927 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aarti Drugs has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aarti Drugs' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aarti Drugs ranks #431 out of 927 companies for Days Payable. This puts Aarti Drugs in the upper half of its industry. The industry median Days Payable is 90.38. Aarti Drugs' value of 96.81 is 7.1% above this benchmark. Historically, Aarti Drugs' own Days Payable has ranged from 73.36 to 104.56 over the past decade. While the company's 10-year median is 78.18 vs. the industry median of 90.38, Aarti Drugs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aarti Drugs's current Days Payable of 96.81 is 7.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aarti Drugs and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aarti Drugs's current Days Payable is 96.81, which is 24% above median its own 10-year median of 78.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Drugs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Drugs (NSE:AARTIDRUGS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹498.33, compared to a current price of ₹396.80 — trading 20.4% below its estimated fair value. The current Days Payable is 96.81, which is 24% above median its 10-year median of 78.18 and 7.1% above the Drug Manufacturers industry median of 90.38. Aarti Drugs' overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Aarti Drugs (NSE:AARTIDRUGS), the current Days Payable is 96.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aarti Drugs (NSE:AARTIDRUGS) Overvalued in 2026?
Based on GuruFocus' analysis, Aarti Drugs stock appears to be undervalued.
The current stock price of ₹396.80 is trading 20.4% below its estimated GF Value™ of ₹498.33.
GuruFocus considers Aarti Drugs to be Modestly Undervalued.
Key valuation signals for NSE:AARTIDRUGS:
Days Payable: 96.81 (24% above median its 10-year median of 78.18)
GF Value™: ₹498.33 vs. price of ₹396.80 (20.4% below fair value)
Industry Position: 7.1% above the Drug Manufacturers median (#431 of 927)
No single metric tells the full story. See the NSE:AARTIDRUGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aarti Drugs Ltd is a pharmaceutical company. It offers active pharmaceutical ingredients (APIs), pharma intermediaries, specialty chemicals, and formulations in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antibiotic, antidiabetic, and vitamins among others. The product offerings of the company comprise Aceclofenac, Celecoxib, Moxifloxacin, and others. The firm caters to both domestic and international markets and derives a majority of its revenue from its business in India.
77GF Score
Get the complete analysis for NSE:AARTIDRUGS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AARTIDRUGS has been successfully added to your 
